OBJECTIVES: The purpose of this study was to assess the efficacy and safety of low-dose (1 mg) daily diethylstilbestrol (DES) for the treatment of castrate-resistant prostate cancer (CRPC). MATERIALS AND METHODS: A retrospective chart review was performed on patients treated with low-dose DES who had CRPC despite anti-androgen withdrawal. The study population consists of 63 patients treated in the pre- and post-chemotherapy settings based on a database review; 58 had sufficient data for efficacy, all were analyzed for safety. RESULTS: A PSA decrease of ≥50% was observed in 19 of 49 pre-chemotherapy patients (39%) with a median time to progression (TTP) of 30 weeks (95% CI, 21.9, 68.7). A PSA decrease of <50% was seen in another 16 patients (33%) with a median TTP of 16.4 weeks (95% CI, 13.0, 37.6). Fourteen patients (29%) had progressive disease by PSA testing; their median TTP was 6.9 weeks (95% CI, 5.6, 12.9). Thromboembolic events included 2 patients with DVTs and 1 patient who developed primary fibrinolysis syndrome. Additional adverse events included gynecomastia in 37 of 63 patients (59%). Secondary observations included PSA responses in 3 of 9 patients treated with DES after chemotherapy progression and a high rate of PSA responses in patients re-treated with DES after a drug holiday. CONCLUSIONS: Low-dose DES is safe and effective in a modern cohort of men with CRPC despite anti-androgen treatment. Its potential role in the post-chemotherapy setting and the suggestion of efficacy on re-challenge merits additional consideration.
OBJECTIVES: The purpose of this study was to assess the efficacy and safety of low-dose (1 mg) daily diethylstilbestrol (DES) for the treatment of castrate-resistant prostate cancer (CRPC). MATERIALS AND METHODS: A retrospective chart review was performed on patients treated with low-dose DES who had CRPC despite anti-androgen withdrawal. The study population consists of 63 patients treated in the pre- and post-chemotherapy settings based on a database review; 58 had sufficient data for efficacy, all were analyzed for safety. RESULTS: A PSA decrease of ≥50% was observed in 19 of 49 pre-chemotherapy patients (39%) with a median time to progression (TTP) of 30 weeks (95% CI, 21.9, 68.7). A PSA decrease of <50% was seen in another 16 patients (33%) with a median TTP of 16.4 weeks (95% CI, 13.0, 37.6). Fourteen patients (29%) had progressive disease by PSA testing; their median TTP was 6.9 weeks (95% CI, 5.6, 12.9). Thromboembolic events included 2 patients with DVTs and 1 patient who developed primary fibrinolysis syndrome. Additional adverse events included gynecomastia in 37 of 63 patients (59%). Secondary observations included PSA responses in 3 of 9 patients treated with DES after chemotherapy progression and a high rate of PSA responses in patients re-treated with DES after a drug holiday. CONCLUSIONS: Low-dose DES is safe and effective in a modern cohort of men with CRPC despite anti-androgen treatment. Its potential role in the post-chemotherapy setting and the suggestion of efficacy on re-challenge merits additional consideration.
Authors: Ramaswamy Manikandan; Shalom J Srirangam; Evelyn Pearson; Stephen C W Brown; Patrick O'Reilly; Gerald N Collins Journal: Urol Int Date: 2005 Impact factor: 2.089
Authors: Jonathan E Rosenberg; Vivian K Weinberg; W Kevin Kelly; Dror Michaelson; Maha H Hussain; George Wilding; Mitchell Gross; Douglass Hutcheon; Eric J Small Journal: Cancer Date: 2007-08-01 Impact factor: 6.860
Authors: Annie M Young; Lucinda J Billingham; Gulnaz Begum; David J Kerr; Ana I Hughes; Daniel W Rea; Stephen Shepherd; Andrew Stanley; Ann Sweeney; Jonathan Wilde; Keith Wheatley Journal: Lancet Date: 2009-02-14 Impact factor: 79.321
Authors: Chris Tran; Samedy Ouk; Nicola J Clegg; Yu Chen; Philip A Watson; Vivek Arora; John Wongvipat; Peter M Smith-Jones; Dongwon Yoo; Andrew Kwon; Teresa Wasielewska; Derek Welsbie; Charlie Degui Chen; Celestia S Higano; Tomasz M Beer; David T Hung; Howard I Scher; Michael E Jung; Charles L Sawyers Journal: Science Date: 2009-04-09 Impact factor: 47.728
Authors: C Serrate; Y Loriot; T De La Motte Rouge; M Gross-Goupil; C Massard; B Escudier; A Bossi; K Fizazi Journal: Ann Oncol Date: 2009-05 Impact factor: 32.976
Authors: Jun Kawakami; Janet E Cowan; Eric P Elkin; David M Latini; Janeen DuChane; Peter R Carroll Journal: Cancer Date: 2006-04-15 Impact factor: 6.860
Authors: Kyle O Rove; E David Crawford; Massimo Perachino; Juan Morote; Laurence Klotz; Paul H Lange; Gerald L Andriole; Alvin M Matsumoto; Samir S Taneja; Mario A Eisenberger; Leonardo O Reis Journal: Urology Date: 2014-04-06 Impact factor: 2.649
Authors: Laura N Vandenberg; Cheryl M Schaeberle; Beverly S Rubin; Carlos Sonnenschein; Ana M Soto Journal: Reprod Toxicol Date: 2013-01-21 Impact factor: 3.143
Authors: A Omlin; C J Pezaro; S Zaidi; D Lorente; D Mukherji; D Bianchini; R Ferraldeschi; S Sandhu; D Dearnaley; C Parker; N Van As; J S de Bono; G Attard Journal: Br J Cancer Date: 2013-08-08 Impact factor: 7.640